CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
36.60
+2.35 (6.86%)
May 8, 2025, 12:19 PM - Market open

Company Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.

It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors.

The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells.

It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D.

It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics.

CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG
CRISPR Therapeutics AG logo
Country Switzerland
Founded 2013
IPO Date Oct 19, 2016
Industry Biotechnology
Sector Healthcare
Employees 393
CEO Samarth Kulkarni

Contact Details

Address:
Baarerstrasse 14
Zug, 6300
Switzerland
Phone 41 41 561 32 77
Website crisprtx.com

Stock Details

Ticker Symbol CRSP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001674416
CUSIP Number H17182108
ISIN Number CH0334081137
Employer ID 47-3173478
SIC Code 2836

Key Executives

Name Position
Dr. Samarth Kulkarni Ph.D. Chief Executive Officer and Chairman
Dr. Raju Yashaswi Prasad Ph.D. Chief Financial Officer
James R. Kasinger J.D. General Counsel and Secretary
Dr. Naimish Patel C.M., M.D. Chief Medical Officer
Shaun Foy CFA Founder
Dr. Emmanuelle Marie Charpentier Ph.D. Co-Founder and Scientific Advisory Board Member
Dr. Craig C. Mello Ph.D. Scientific Founder and Advisory Board Member
Dr. Chad A. Cowan Ph.D. Scientific Founder
Dr. Matthew Porteus M.D., Ph.D. Scientific Founder and Advisory Board Member
Dr. Daniel G. Anderson Ph.D. Scientific Founder and Advisory Board Member

Latest SEC Filings

Date Type Title
May 6, 2025 10-Q Quarterly Report
May 6, 2025 8-K Current Report
Apr 16, 2025 ARS Filing
Apr 16, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 16, 2025 DEF 14A Other definitive proxy statements
Apr 3, 2025 PRE 14A Other preliminary proxy statements
Mar 26, 2025 8-K Current Report
Feb 18, 2025 144 Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 11, 2025 10-K Annual Report